Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04702451 · ClinicalTrials.gov registry record · NA
Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation
A NA study, sponsored by Volta Medical.
- Completed
- Registry status
- NA
- Development phase
- 377
- Enrollment target
NCT04702451: Completed NA study, sponsored by Volta Medical.
NCT04702451 is a NA study that has completed, run by Volta Medical. The registered enrollment target is 377 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04702451, a NA study, has completed, sponsored by Volta Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 377 participants
- Enrollment target
Study Summary
Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest. This procedure is referred to as Pulmonary Vein Isolation (PVI). The hypothesis in this Study is that a tailored ablation strategy targeting areas of spatio-temporal dispersion in combination with PVI is superior to an anatomical ablation strategy targeting PVI alone for the treatment of persistent AF.
Primary Outcome
Freedom from documented AF episodes \> 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure
Interventions
- PROCEDURE Dispersion ablation + PVI
- DEVICE VX1
- PROCEDURE PVI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2023-12-27 |
| Phase | NA |
What the finished NCT04702451 record still lists
NCT04702451 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 3 interventions - of which Dispersion ablation + PVI is the first listed.
NCT04702451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04702451 about?
NCT04702451 is a clinical study titled "Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation". Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest. This procedure is referred to as Pulmonary Vein Isolation (PVI). The hypothesis in this Study is that a tailored ablation str...
What is the current status of trial NCT04702451?
This trial is currently completed. It is a NA study. The enrollment target is 377 participants. The study started on 2021-02-12. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT04702451?
The interventions under investigation include: Dispersion ablation + PVI (PROCEDURE), VX1 (DEVICE), PVI (PROCEDURE).
Who is sponsoring clinical trial NCT04702451?
This trial is sponsored by Volta Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04702451's enrollment target sits among peer trials
377 274th of 2000 higher than 1,727 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI